Fundraising Fox
中裕新藥
Founded 2007 · 49 employees on LinkedIn · 1 known investors
Find your way into 中裕新藥
Sign up to find every way you can get introduced to 中裕新藥
- Your email: who you already know at 中裕新藥, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 中裕新藥 team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
Founders & leadership
JC
Jimmy ChangCEO
Investors · 1
Frequently asked questions
- What does 中裕新藥 do?
- TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
- Who are 中裕新藥's investors?
- 中裕新藥's investors include YFY Biotech Management Company.